Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 3:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 124 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Parkinson's Disease
Interventions
ND0612
Drug
Lead sponsor
NeuroDerm Ltd.
Industry
Eligibility
30 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
26
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Fountain Valley, California + 23 more
Conditions
Parkinson's Disease (PD)
Interventions
ABBV-951, Placebo for Levodopa/Carbidopa (LD/CD), Levodopa/Carbidopa (LD/CD), Placebo for ABBV-951
Drug
Lead sponsor
AbbVie
Industry
Eligibility
30 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
70
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 62 more
Conditions
Parkinson's Disease
Interventions
Istradefylline (KW-6002)
Drug
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
30 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Princeton, New Jersey
Conditions
Parkinson's Disease
Interventions
IPX066, CLE
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
30 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
12
States / cities
Fresno, California • Sunnyvale, California • Miami, Florida + 9 more
Conditions
Major Depressive Disorder, Dysthymia, Depression
Interventions
L-DOPA, Placebo Oral Tablet
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
60 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Conditions
Brain Injury
Interventions
Polypharmacy using FDA-approved products, Median Nerve Stimulation (MNS), Nutraceutical Supplementation, Standard of Care
Drug · Device · Dietary Supplement + 1 more
Lead sponsor
International Brain Research Foundation
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Edison, New Jersey
Conditions
Parkinson's Disease
Interventions
Carbidopa/levodopa/entacapone, Immediate release carbidopa/levodopa
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
30 Years to 70 Years
Enrollment
747 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
31
States / cities
Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 25 more
Conditions
Parkinson's Disease
Interventions
CVT-301, Sinemet
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
30 Years to 85 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
5
States / cities
Long Beach, California • Hallandale, Florida • Orlando, Florida + 2 more
Conditions
Stroke
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

1/2-Dopaminergic Dysfunction in Late-Life Depression (The D3 Study)

NCT04493320
Conditions
Depression, Cognitive Impairment, Gait Impairment
Interventions
Carbidopa/levodopa, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
60 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
New York, New York
Conditions
Parkinson's Disease
Interventions
KW-6002 (istradefylline)
Drug
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
30 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Princeton, New Jersey
Conditions
Parkinson Disease
Interventions
CREXONT ER
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
27
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Aliso Viejo, California + 22 more
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Medications for Stopping Cocaine Dependence and Preventing Relapse

NCT00218023
Conditions
Cocaine Abuse, Cocaine-Related Disorders
Interventions
Modafinil, Levodopa/Carbidopa, Naltrexone HCl, Placebo, Motivational Interviewing (MI), Contingency management (CM), Cognitive-Behavioral Therapy (CBT)
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 55 Years
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Houston, Texas
Conditions
Age-related Macular Degeneration
Interventions
carbidopa-levodopa 25-100 mg, placebo for carbidopa-levodopa 25-100 mg
Drug
Lead sponsor
Snyder, Robert W., M.D., Ph.D., P.C.
Individual
Eligibility
50 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tucson, Arizona
Conditions
Spinal Cord Injuries
Interventions
5HTP, L-DOPA, Placebo oral tablet, Carbidopa
Drug
Lead sponsor
Jessica M D'Amico
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Louisville, Kentucky
Conditions
Parkinson's Disease
Interventions
Sinemet 25-100 Oral Tablet, XP21279, Carbidopa Pill
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
30 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Peoria, Arizona • Bingham Farms, Michigan
Conditions
Cocaine Abuse, Cocaine-Related Disorders
Interventions
Levodopa, Carbidopa, Clinical Management, Relapse Prevention Therapy, Contingency Management
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 55 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
Houston, Texas
Conditions
Parkinson's Disease
Interventions
IPX066 95 mg, IPX066 145 mg, IPX066 195 mg, IPX066 245 mg
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
30 Years and older
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 30 more
Not listed Phase 2 Interventional Accepts healthy volunteers

Proof of Mechanism Study for the Treatment of Social Anhedonia in ASD

NCT03243552
Conditions
ASD
Interventions
L-DOPA versus Placebo, Social Skills Training
Drug · Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
13 Years to 30 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Striatal Effective Connectivity to Predict Treatment Response in Cocaine Misuse

NCT02080819
Conditions
Cocaine Dependence
Interventions
levodopa/carbidopa 400/100 BID
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 50 Years
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Richmond, Virginia
Suspended Early Phase 1 Interventional Accepts healthy volunteers

Changes in Glutamatergic Neurotransmission of Severe TBI Patients

NCT04244058
Conditions
Disorder of Consciousness, Traumatic Brain Injury
Interventions
Amantadine + L-DOPA, NMDA blocker
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Conditions
Parkinson Disease, Tremor
Interventions
Istradefylline Pill
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
McLean, Virginia
Conditions
Parkinson's Disease
Interventions
IPX054 200 mg, CD-LD IR, IPX054 Placebo, CD-LD IR Placebo
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
30 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Chicago, Illinois • Charleston, South Carolina
Conditions
Parkinson Disease
Interventions
Neurostimulation, Carbidopa 25/Levodopa 100Mg Tab
Device · Drug
Lead sponsor
David Escobar
Other
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio